Skip to main content
. 2021 Sep 17;4(5):1689–1701. doi: 10.1021/acsptsci.1c00184

Figure 4.

Figure 4

Efficacy of l-NaAA for CD44-targeted NIR-PIT in an MC38-luc tumor model. (a) Treatment schedule. (b) Fluorescence imaging and (c) mean 700 nm fluorescence intensity before and after CD44-targeted NIR-PIT with or without l-NaAA in the MC38-luc tumor-bearing mouse (n = 10, mean ± SEM; paired t-test; N.S., not significant). (d) BLI before (day 6) and after (days 8–12) CD44-targeted NIR-PIT in MC38-luc tumor bearing mice. (e) Luciferase activity calculated from BLI (n = 10; repeated measure two-way ANOVA, followed by Tukey’s test; ****p < 0.0001; N.S., not significant). (f) Edema formation (red arrowhead) was shown 1 day after CD44-targeted NIR-PIT. (g) Body weight curve (n = 10, mean ± SEM; repeated measure two-way ANOVA, followed by Tukey’s test; N.S., not significant). (h) T2WI fat-sat MRI imaging 1 day after NIR-PIT. The red arrowhead shows the MC38-luc subcutaneous tumor. (i) Mean high intensity area calculated from coronal T2WI fat-sat MR images (n = 3, mean ± SEM; unpaired t-test; *p < 0.05).